Mont-Saint-Guibert, Belgium – The biotechnology company, Cardio3 BioSciences SA (Cardio3 BioSciences), a leader in the discovery and development of regenerative, protective and reconstructive therapies for the treatment of cardiac diseases, was granted on July 24 2013 qualification as an “Innovative Company” by BpiFrance. Cardio3 BioSciences’ stock (ticker symbol: CARD) thereby becomes eligible for investments made by FCPI (Fonds Commun de Placement dans l’Innovation) funds in France. Those funds invest in innovative companies and benefit from special tax incentives for those investments.

This qualification has been obtained in part due to the collaboration of the Company with AP-HH (Assistance Publique - Hôpitaux de Paris (a leading group of public hospitals in Paris), other academic partners and SMEs with a view to developing a biodegradable prothesis seeded with cells and/or proteins for the replacement of the Right Ventircular Outflow Tract (RVOT) in patients with congenital heart disease.

Dr. Christian Homsy, CEO of Cardio3 BioSciences: “We are proud that Cardio3 BioSciences has been recognized as an “Innovative Company” by BpiFrance. This qualification will allow FCPI funds to acquire shares of the company, thereby potentially enlarging our shareholder base in France.”

Download press release(s)

Communiqué de presse

653.78 Ko

Press release

653.78 Ko

Cardio3 Biosciences announces half year financial results and business update

Next News

Cardio3 Biosciences announces half year financial results and business update